FOXC1 and luminal B breast carcinoma: Taken together, these data provide compelling evidence that pharmacological intervention targeting the EZH2-dependent repression of a FOXC1-driven transcriptional program can hinder the metastatic properties of human Luminal B breast cancer (Fig. 8).